See more : Lupatech S.A. (LUPA3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Nippon Shinyaku Co., Ltd. (4516.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nippon Shinyaku Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Counter Press Acquisition Corporation (CPAQW) Income Statement Analysis – Financial Results
- Troy Gold & Mineral Corp (TGMR) Income Statement Analysis – Financial Results
- Avisana Corp. (AVSA) Income Statement Analysis – Financial Results
- Ashanti Sankofa Inc. (AMIQF) Income Statement Analysis – Financial Results
- Providence Resources P.l.c. (PZQA.IR) Income Statement Analysis – Financial Results
Nippon Shinyaku Co., Ltd. (4516.T)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.nippon-shinyaku.co.jp
About Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 148.26B | 144.18B | 137.48B | 121.89B | 116.64B | 114.72B | 101.45B | 98.78B | 84.21B | 79.99B | 76.52B | 69.94B | 67.30B | 63.55B | 62.96B | 63.05B | 59.44B | 56.32B | 53.96B | 54.25B |
| Cost of Revenue | 51.24B | 55.98B | 50.19B | 49.95B | 53.16B | 50.95B | 46.93B | 44.84B | 44.02B | 41.23B | 39.03B | 34.78B | 32.70B | 30.22B | 29.02B | 28.89B | 27.37B | 25.12B | 23.31B | 23.15B |
| Gross Profit | 97.02B | 88.20B | 87.29B | 71.93B | 63.48B | 63.76B | 54.52B | 53.95B | 40.19B | 38.77B | 37.48B | 35.17B | 34.60B | 33.33B | 33.94B | 34.16B | 32.07B | 31.21B | 30.65B | 31.10B |
| Gross Profit Ratio | 65.44% | 61.17% | 63.49% | 59.02% | 54.43% | 55.58% | 53.74% | 54.61% | 47.73% | 48.46% | 48.99% | 50.28% | 51.41% | 52.45% | 53.91% | 54.18% | 53.96% | 55.41% | 56.80% | 57.33% |
| Research & Development | 31.68B | 24.14B | 22.86B | 16.10B | 13.99B | 16.70B | 13.22B | 14.90B | 9.74B | 8.97B | 9.53B | 9.05B | 9.41B | 8.97B | 8.44B | 7.85B | 7.90B | 8.20B | 10.07B | 8.49B |
| General & Administrative | 29.11B | 34.81B | 32.17B | 29.39B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.61B | 2.53B | 2.63B | 2.56B | 2.37B | 2.55B | 2.59B | 2.64B |
| Selling & Marketing | 4.85B | 5.91B | 5.52B | 4.98B | 5.20B | 4.97B | 3.90B | 3.01B | 2.63B | 2.01B | 1.38B | 1.03B | 1.09B | 1.25B | 1.24B | 1.20B | 1.04B | 0.00 | 0.00 | 0.00 |
| SG&A | 33.96B | 34.81B | 32.17B | 4.98B | 5.20B | 4.97B | 3.90B | 3.01B | 2.63B | 2.01B | 1.38B | 1.03B | 3.70B | 3.78B | 3.87B | 3.76B | 3.41B | 2.55B | 2.59B | 2.64B |
| Other Expenses | 0.00 | 0.00 | -691.00M | -95.00M | 67.00M | 147.00M | 133.00M | 49.00M | -52.00M | -61.00M | 305.00M | 137.00M | 358.00M | 440.00M | 210.00M | 373.00M | 382.00M | -20.00M | 311.00M | 58.00M |
| Operating Expenses | 65.63B | 58.15B | 54.35B | 45.79B | 41.81B | 43.12B | 37.44B | 38.66B | 31.64B | 30.20B | 29.44B | 28.26B | 21.12B | 20.68B | 20.07B | 19.11B | 18.73B | 19.19B | 21.39B | 19.78B |
| Cost & Expenses | 116.87B | 114.13B | 104.54B | 95.75B | 94.97B | 94.07B | 84.37B | 83.50B | 75.66B | 71.42B | 68.48B | 63.04B | 53.82B | 50.90B | 49.09B | 48.00B | 46.09B | 44.31B | 44.70B | 42.93B |
| Interest Income | 650.00M | 575.00M | 472.00M | 21.00M | 17.00M | 16.00M | 26.00M | 39.00M | 26.00M | 28.00M | 32.00M | 27.00M | 28.00M | 41.00M | 98.00M | 211.00M | 167.00M | 132.00M | 96.00M | 91.00M |
| Interest Expense | 329.00M | 136.00M | 119.00M | 2.00M | 2.00M | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M | 4.00M | 8.00M | 9.00M | 9.00M | 10.00M | 14.00M | 28.00M | 41.00M | 57.00M | 90.00M |
| Depreciation & Amortization | 5.02B | 5.04B | 4.59B | 4.40B | 3.47B | 3.42B | 2.77B | 2.65B | 2.45B | 2.67B | 2.70B | 2.76B | 2.95B | 3.12B | 3.08B | 2.88B | 2.85B | 2.75B | 2.69B | 3.02B |
| EBITDA | 38.70B | 34.27B | 36.59B | 32.09B | 25.14B | 24.96B | 19.85B | 17.93B | 11.00B | 11.60B | 10.74B | 10.05B | 9.15B | 9.06B | 10.08B | 10.58B | 9.75B | 8.08B | 6.03B | 12.74B |
| EBITDA Ratio | 26.10% | 24.74% | 27.65% | 24.87% | 21.98% | 21.76% | 19.94% | 19.13% | 13.24% | 14.50% | 14.83% | 14.31% | 24.86% | 25.13% | 27.12% | 29.19% | 27.71% | 26.41% | 22.91% | 26.70% |
| Operating Income | 31.39B | 30.05B | 32.95B | 26.13B | 21.67B | 20.64B | 17.08B | 15.28B | 8.55B | 8.56B | 8.04B | 6.90B | 13.48B | 12.65B | 13.87B | 15.05B | 13.35B | 12.02B | 9.26B | 11.32B |
| Operating Income Ratio | 21.17% | 20.84% | 23.96% | 21.44% | 18.58% | 18.00% | 16.84% | 15.47% | 10.15% | 10.70% | 10.50% | 9.87% | 20.03% | 19.91% | 22.03% | 23.87% | 22.46% | 21.33% | 17.17% | 20.87% |
| Total Other Income/Expenses | 2.23B | 440.00M | 353.00M | 1.56B | 774.00M | 896.00M | 372.00M | 197.00M | 403.00M | 366.00M | 560.00M | 384.00M | 181.00M | -6.72B | -6.87B | -7.37B | -6.47B | -6.73B | -5.98B | -1.69B |
| Income Before Tax | 33.62B | 30.49B | 33.30B | 28.76B | 22.44B | 21.54B | 17.45B | 15.48B | 8.95B | 8.93B | 8.60B | 7.21B | 6.19B | 5.94B | 6.99B | 7.69B | 6.88B | 5.29B | 3.29B | 9.63B |
| Income Before Tax Ratio | 22.67% | 21.15% | 24.22% | 23.60% | 19.24% | 18.78% | 17.20% | 15.67% | 10.63% | 11.16% | 11.24% | 10.31% | 9.20% | 9.34% | 11.11% | 12.19% | 11.57% | 9.39% | 6.09% | 17.75% |
| Income Tax Expense | 7.76B | 7.67B | 8.30B | 8.04B | 5.55B | 5.22B | 4.48B | 3.71B | 2.61B | 3.04B | 2.84B | 2.63B | 2.46B | 1.96B | 2.88B | 3.18B | 2.84B | 2.38B | 1.66B | 4.00B |
| Net Income | 25.85B | 22.81B | 24.99B | 19.54B | 16.87B | 16.30B | 12.95B | 11.75B | 6.34B | 5.88B | 5.75B | 4.65B | 3.72B | 3.96B | 4.10B | 4.50B | 4.03B | 2.90B | 1.61B | 5.64B |
| Net Income Ratio | 17.44% | 15.82% | 18.17% | 16.03% | 14.46% | 14.21% | 12.77% | 11.89% | 7.53% | 7.35% | 7.51% | 6.64% | 5.52% | 6.23% | 6.51% | 7.14% | 6.78% | 5.15% | 2.99% | 10.39% |
| EPS | 383.82 | 338.70 | 370.97 | 290.11 | 250.41 | 242.03 | 192.31 | 174.42 | 94.10 | 87.26 | 85.25 | 68.87 | 55.04 | 58.62 | 60.63 | 66.56 | 59.57 | 42.73 | 22.84 | 81.22 |
| EPS Diluted | 383.82 | 338.70 | 370.97 | 290.11 | 250.41 | 242.03 | 192.31 | 174.42 | 94.10 | 87.26 | 85.25 | 68.87 | 55.04 | 58.62 | 60.63 | 66.56 | 59.57 | 42.73 | 22.84 | 81.22 |
| Weighted Avg Shares Out | 67.35M | 67.35M | 67.35M | 67.35M | 67.35M | 67.35M | 67.36M | 67.36M | 67.37M | 67.41M | 67.46M | 67.49M | 67.50M | 67.53M | 67.56M | 67.60M | 67.67M | 67.87M | 68.19M | 68.58M |
| Weighted Avg Shares Out (Dil) | 67.35M | 67.35M | 67.35M | 67.35M | 67.35M | 67.35M | 67.36M | 67.36M | 67.37M | 67.41M | 67.46M | 67.49M | 67.50M | 67.53M | 67.56M | 67.60M | 67.67M | 67.87M | 68.19M | 68.58M |
Source: https://incomestatements.info
Category: Stock Reports